Hoth Therapeutics, Inc (NASDAQ:HOTH) is gaining a bit in the morning session on Tuesday. The stock has been in a downtrend since the beginning of the year.
Hoth Therapeutics Plans Shareholder Presentation on HT-KIT Therapeutic’s Preclinical Results for Rare Cancers
- announced today plans to host a virtual information session on its pipeline product, HT-KIT, a new molecular entity under development for treatment of mast cell-derived cancers and anaphylaxis, on Thursday, June 3rd for interested shareholders. Dr. Glenn Cruse, Ph.D., Assistant Professor at North Carolina State University, who developed HT-KIT, will present the preclinical animal results that are part of the Company’s ASCO Exhibition.
- HT-KIT exhibited highly positive results in humanized mast cell neoplasm models, representative in vitro and in vivo models for aggressive, mast cell-derived cancers such as mast cell leukemia and mast cell sarcoma. The anti-cancer therapeutic, which is currently in development, uses mRNA frame shifting that induces apoptosis of neoplastic mast cells.
- These findings show that the novel anti-cancer therapeutic rapidly induces apoptosis and cell death in neoplastic mast cells. Furthermore, systemic administration of the anti-cancer therapeutic in an in vivo humanized mast cell neoplasm model showed a significant reduction in tumors and neoplastic mast cell infiltration from the therapeutic group compared to the vehicle control group.
- There were no obvious signs of toxicity in the study animals, suggesting that the novel anti-cancer therapeutic was well-tolerated.
“Hoth Therapeutics is pleased to share greater details on the development of Dr. Glenn Cruse’s HT-KIT and the potential it has to help alleviate pain for patients living with gastrointestinal stromal tumors, certain cancers and anaphylaxis,” said Robb Knie, Chief Executive Office of Hoth Therapeutics, Inc
As of 12:03, HOTH is trading at $1.49, up 2.75%. So far more than 451K shares have exchanged hands, compared to its average volume of 3.13 million shares.